2008
DOI: 10.1517/17425255.4.11.1371
|View full text |Cite
|
Sign up to set email alerts
|

Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
29
0
1

Year Published

2010
2010
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 46 publications
(3 reference statements)
1
29
0
1
Order By: Relevance
“…Interestingly, the number of empty lacunae in the submucosal bone significantly increased after long-term treatment, suggesting that this finding may be associated with the cumulative doses fixed in the alveolar bone. This fact is in agreement with previous clinical and experimental reports (Ruggiero et al 2009;Marx et al 2005;Allen 2008;Aguirre et al 2012), supporting the hypothesis that long-term exposure to high doses of aminobisphosphonates determines their accumulation in alveolar BMUs, inducing local changes and constituting a potential first step in the development of osteonecrosis of the jaw (Allen 2008;Hoff et al 2008;Daubiné et al 2007;Pozzi et al 2009). …”
Section: Discussionsupporting
confidence: 89%
“…Interestingly, the number of empty lacunae in the submucosal bone significantly increased after long-term treatment, suggesting that this finding may be associated with the cumulative doses fixed in the alveolar bone. This fact is in agreement with previous clinical and experimental reports (Ruggiero et al 2009;Marx et al 2005;Allen 2008;Aguirre et al 2012), supporting the hypothesis that long-term exposure to high doses of aminobisphosphonates determines their accumulation in alveolar BMUs, inducing local changes and constituting a potential first step in the development of osteonecrosis of the jaw (Allen 2008;Hoff et al 2008;Daubiné et al 2007;Pozzi et al 2009). …”
Section: Discussionsupporting
confidence: 89%
“…Bisphosphonates are cost-effective treatment for management of osteoporosis and they reduce morbidity, disability, and mortality associated with fractures [1][2][3][4][5][6][7][8][9][10][11][12][13]. However, our observations suggest care must be taken when prescribing bisphosphonates for prolonged periods and doctors should be alerted by symptoms of thigh pain in patients taking them, because this may be a symptom of insufficiency changes in the femoral shaft.…”
Section: Discussionmentioning
confidence: 82%
“…In addition, chronic oversuppression of bone turnover by bisphosphonates may allow secondary mineralization to continue, producing hypermineralized bone that may be more brittle [2,13,18,46,59]. Other theories to explain this association have been proposed, including those relating bone brittleness caused by long-term alendronate therapy to trabecular bone collagen cross-linking and isomerization [3,55]. Others suggest it may be attributable to osteoclastic abnormalities or a variant form of osteoporosis [6,65].…”
Section: Introductionmentioning
confidence: 99%
“…They reduce bone resorption and bone loss either through the inhibition of the protein prenylation or the accumulation of toxic metabolites [66]. Some bisphosphonates are more tolerated than others; specifically, the adverse effects of alendronate are relatively mild with some transient gastrointestinal tract problems and some serious but uncommon events (esophagitis, gastric/duodenal ulceration/bleeding) [67].…”
Section: Current Treatment Optionsmentioning
confidence: 99%